Navigation Links
Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013

CRANBURY, N.J., Nov. 14, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2013. 

Recent Highlights
Bremelanotide development for Female Sexual Dysfunction (FSD):

  • Successful completion of device bioequivalence trial
  • Receipt of a $1.0 million, non-refundable option fee relating to negotiation of a potential future license of bremelanotide in a defined territory outside North America
  • Pivotal Phase 3 clinical trials anticipated to start in the first quarter of calendar year 2014
  • The Company obtained patents during the quarter:

  • U.S. Patent 8,487,073, entitled "Melanocortin Receptor-Specific Peptides for Treatment of Sexual Dysfunction" issued July 16, 2013, claiming composition of matter on novel peptides for treatment of sexual dysfunction, obesity and related indications
  • U.S. Patent No. 8,492,517, entitled "Melanocortin-1 Receptor-Specific Cyclic Peptides" issued July 23, 2013, claiming composition of matter of lead peptides for treatment of inflammation-related diseases
  • First Quarter Fiscal 2014 Financial Results
    Palatin reported a net loss of $4.5 million, or $(0.04) per basic and diluted share, for the quarter ended September 30, 2013, compared to a net loss of $10.5 million, or $(0.15) per basic and diluted share, for the same period in 2012.The decrease in net loss for the quarter ended September 30, 2013 compared to the same period last fiscal year was mainly attributable to the recognition of a $7.1 million, non-operating expense, in the quarter ended September 30, 2012, which represented the increase in fair value of warrants issued in connection with Palatin's private placement that closed on July 3, 2012.

    There were no revenues recorded in the quarter ended September 30, 2013, compared to $4,000 for the same period in 2012.  Revenue consisted entirely of reimbursement of development costs and per-employee compensation earned at the contractual rate pursuant to Palatin's license agreement with AstraZeneca. 

    Operating Expenses
    For the quarter ended September 30, 2013, total operating expenses were $4.5 million compared to $3.4 million for the comparable quarter of 2012.  The increase in operating expenses for the quarter ended September 30, 2013 was the result of an increase in costs primarily relating to Palatin's bremelanotide for the treatment of FSD program.

    Cash Position
    Palatin's cash, cash equivalents and short-term investments were $22.3 million as of September 30, 2013, compared to cash, cash equivalents and short-term investments of $24.4 million at June 30, 2013.  Current liabilities were $4.2 million as of September 30, 2013 compared to $2.1 million as of June 30, 2013.

    Palatin believes its existing capital resources will be adequate to fund its currently planned operations, including submitting complete protocols for pivotal Phase 3 studies to the U.S. Food and Drug Administration (FDA) but not initiating patient enrollment, through at least calendar year 2014.

    Conference Call / Webcast
    Palatin will host a conference call and webcast on November 14, 2013 at 10:00 a.m. Eastern Time to discuss the results of operations in greater detail and an update on corporate developments including the status of partnering Bremelanotide for sexual dysfunction in the United States and Europe.  Individuals interested in listening to the conference call live can dial 1-888-280-4443 (domestic) or 1-719-457-2601 (international), pass code 3153901.  The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at  A telephone and webcast replay will be available approximately one hour after the completion of the call.  To access the telephone replay, dial 1-888-203-1112 (domestic) or 1-719-457-0820 (international), pass code 3153901.  The webcast and telephone replay will be available through November 21, 2013. 

    About Palatin Technologies, Inc.
    Palatin Technologies, Inc. is a biopharmaceutical company developing targeted, receptor- specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential.  For additional information regarding Palatin, please visit Palatin's website at

    Forward-looking Statements
    Statements in this press release that are not historical facts, including statements about future expectations of Palatin Technologies, Inc., such as statements about clinical trial results, potential actions by regulatory agencies including the FDA, regulatory plans, development programs, proposed indications for product candidates and market potential for product candidates, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin's actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin's actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and the need for regulatory approvals, Palatin's ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin's products, and other factors discussed in Palatin's periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

    (Financial Statement Data Follows)PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Statements of Operations(unaudited)Three Months Ended September 30,20132012REVENUES:

    3,806OPERATING EXPENSES:Research and development

    3,449,1402,343,313General and administrative

    1,043,5101,061,016Total operating expenses

    4,492,6503,404,329Loss from operations

    (4,492,650)(3,400,523)OTHER INCOME (EXPENSE):Investment income

    5,31914,371Interest expense

    (1,851)(2,282)Increase in fair value of warrants

    -(7,069,165)Gain on disposition of supplies and equipment

    -4,620Total other income (expense), net

    3,468(7,052,456)NET LOSS

    (10,452,979)Basic and diluted net loss per common share

    (0.15)Weighted average number of common shares

    outstanding used in computing basic and diluted net

    loss per common share

    106,609,72071,669,170 PALATIN TECHNOLOGIES, INC.and SubsidiaryConsolidated Balance Sheets(unaudited)September 30, 2013June 30, 2013ASSETSCurrent assets:Cash and cash equivalents

    9,167,632Short-term investments

    3,749,9265,249,654Prepaid expenses and other current assets

    251,703332,267Total current assets

    22,586,72224,749,553Property and equipment, net

    245,412266,415Other assets

    57,92558,131Total assets

    25,074,099LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Capital lease obligations

    9,909Accounts payable 

    990,898338,726Accrued expenses

    2,191,4211,701,727Unearned revenue

    1,000,000-Total current liabilities

    4,196,3872,060,362Deferred rent

    26,15535,460Total liabilities

    4,222,5422,095,822Stockholders' equity:Preferred stock of $0.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,697 shares as of September 30, 2013 and June 30, 2013 

    4747Common stock of $0.01 par value – authorized 300,000,000 shares; issued and outstanding 39,191,655 shares as of September 30, 2013 and 39,116,948 as of June 30, 2013, respectively

    391,917391,169Additional paid-in capital

    282,870,194282,692,520Accumulated deficit 

    (264,594,641)(260,105,459)Total stockholders' equity

    18,667,51722,978,277Total liabilities and stockholders' equity



    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
    3. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
    4. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
    5. Palatin Technologies Reports Successful Completion Of Device Bioequivalence Trial
    6. Palatin Technologies, Inc. To Report First Quarter Fiscal Year 2014 Results; Teleconference and Webcast to be held on November 14, 2013
    7. Palatin Technologies Announces Issuance of Two Natriuretic Peptide Receptor-Specific Mimetic Patents
    8. Palatin Technologies Announces Option for License to Bremelanotide in Europe
    9. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
    10. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
    11. Radiation Control Technologies, Inc. Announces Exclusive License to Two Patents from the National Institutes of Health
    Post Your Comments:
    (Date:10/8/2015)... Oct. 8, 2015  Allergan plc (NYSE: AGN ... it will hold its R&D Day on November 4, ... – to 1:00 p.m. PT). The company will also ... at 9:00 a.m. ET (6:00 a.m. PT). ... --> Logo - ...
    (Date:10/8/2015)... CAMBRIDGE, Mass. , Oct. 8, 2015 /PRNewswire/ ... has awarded approximately $40 million to the Broad ... whole genome sequencing of 20,000 individuals, as well ... sequencing and metabolite profiling. Trans-Omics for ... an initial step toward a larger initiative, which ...
    (Date:10/8/2015)... FRANCISCO , Oct. 8, 2015  Nektar Therapeutics ... the Company,s pain and oncology portfolio during an Investor ... - 3:30 p.m. Eastern Time in New ... carcinoma.  Details of the NKTR-214 Phase 1/2 clinical program ... CD122-biased immune-stimulatory cytokine designed to preferentially stimulate the production ...
    Breaking Medicine Technology:
    ... (SIX: RO, ROG; OTCQX: RHHBY) announced today that the David ... be using the Roche LightCycler ® 480 System, a ... gene expression and genetic variation, in advanced cancer research. ... 480 System to support several key areas of research it ...
    ... 2011 /PRNewswire/ -- Royal Philips Electronics ... States availability of the Ingenia MRI system, the ... Previously available in Europe, Canada and Japan, the ... Food and Drug Administration. Driven by Philips commitment ...
    Cached Medicine Technology:
    (Date:10/9/2015)... (PRWEB) , ... October 09, 2015 , ... ... company, has announced the final product specifications for TRACTUS, the world’s first sterile ... in the United States in response to the FDA’s recent Unique Device Identifier ...
    (Date:10/9/2015)... ... October 09, 2015 , ... Cambias Insurance Agency, ... communities, is initiating a combined charity effort with Animal Rescue New Orleans in ... Louisiana. , Animal Rescue New Orleans is a non-profit organization committed to ...
    (Date:10/9/2015)... ... , ... ViewPoint Center, a teen mental health hospital for youth ... stigma associated with mental illness causes many to hide away in shame rather than ... teens with mental illness , providing teens with comprehensive diagnostic assessment and treatment. ...
    (Date:10/9/2015)... ... October 09, 2015 , ... ... placement counseling, recently opened its newest office in Maryland – its Bethesda ... with a background as a project management technology consultant to many of the ...
    (Date:10/9/2015)... Florida (PRWEB) , ... October 09, 2015 , ... A variety of race options will ... Treatment of Co-occurring Disorders on Sunday, October 18, at Al Lopez Park, 4810 North Himes ... and will include the choice of a 5K run or walk and a one-mile walk, ...
    Breaking Medicine News(10 mins):
    ... to be used for treating patients with osteoporosis//, but scientists ... observe the changes in the bone mineral density. ,A ... drug strontium ranelate have an effect on the bone mineral ... advantage of the treatment procedure. The recent studies on the ...
    ... out that people who regularly drink large amount of alcohol are ... causes than binge drinkers, who drink a lot of alcohol in ... had more than enough attention given to young alcohol consumers who ... maximum, these people may be more at risk from violent assaults ...
    ... An interesting prospective study undertaken by the researchers at Massachusetts ... shown that higher intake of low-fat dairy may lower the ... II diabetes, either the body does not produce enough insulin ... the body to be able to use sugar. Type II ...
    ... have shown that placebo treatment can reduce the nature ... experiences. ,Placebo treatment consists of dummy medication or ... tablets, saline water injections etc. ,In the new ... have shown that placebo treatment can effectively control the ...
    ... said that stomach infections caused by Helicobacter pylori ... ,Helicobacter pylori are common bacteria that reside ... causes stomach infections. Previous research had connected the ... tracts, and ischemic heart disease. ,Researchers have ...
    ... the proper structure// and function of cell membranes and ... animal studies have shown that high intake of polyunsaturated ... is a clouding of the normally clear lens of ... of blindness in the world today. Besides the physical ...
    Cached Medicine News:
    CDIs new improved Implant Stabilizer has super-soft elastic bands with lace trim....
    Bras and Breast Support...
    Post-Surgical compression garments...
    ... The Albumin Cobalt Binding (ACB®) Test is ... Modified Albumin (IMA®) by measuring the cobalt ... serum sample. First identified in the early ... comes in contact with ischemic tissue in ...
    Medicine Products: